The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

The present invention relates to a composition wherein olopatadine is stably dissolved and a process thereof.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt’s Disease.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt’s Disease.

The present disclosure provides methods of treating subjects having skin cancer or at risk of developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Described herein are compositions for treating dermatological conditions, such as skin conditions, as well as neuropathological conditions and disorders, particularly those requiring relief from pain and physical discomfort. The compositions as described may be topically or transdermally administered. In some aspects, the compositions and products comprise a pharmaceutically acceptable amount of at least one analgesic component and a cannabis component and are useful to relieve acute or chronic pain, inflammation, and the like, following application.